Director Program Operations Leader, Oncology
Regeneron Pharmaceuticals
About this role
The Director Program Operations Leader (POL) is responsible for leading and implementing the operational strategy for complex clinical trial programs in Oncology. They oversee clinical operations activities, manage staff, and ensure the success of clinical studies within regulatory and company standards.
Skills
Qualifications
About Regeneron Pharmaceuticals
regeneron.comDiscover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
Recent company news
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN
4 hours ago
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
6 hours ago
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative?
1 day ago
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN)
1 day ago
Capital Research Global Investors Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN
7 hours ago
About Regeneron Pharmaceuticals
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Leadership Team
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
Unlock Company Insights
View leadership team, funding history,
and employee contacts for Regeneron Pharmaceuticals.
Salary
$205k – $342k
per year
More jobs at Regeneron Pharmaceuticals
Similar Jobs
Executive Director, Clinical Development Operations (Early Oncology)
AstraZeneca
Associate Director, TMF Operations
Systimmune
Clinical Operations Associate Director (Biotech Oncology)
Exelixis
Executive Director, Clinical Development Operations (Early Oncology)
AstraZeneca
Director, Clinical Operations, Oncology
Takeda Pharmaceutical Company
Director, Clinical Operations, Therapeutics and Oncology
Moderna